kabutan

Japan Tissue Engineering Co., Ltd.(7774) Summary

7774
TSE Growth
Japan Tissue Engineering Co., Ltd.
507
JPY
0
(0.00%)
Dec 5, 1:27 pm JST
3.27
USD
Dec 4, 11:27 pm EST
Result
PTS
outside of trading hours
509
Dec 5, 11:28 am JST
Summary Chart Historical News Financial Result
PER
142.0
PBR
3.78
Yield
ー%
Margin Trading Ratio
51.80
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
509 JPY 3.28 USD
Previous Close Dec 4
507 JPY 3.26 USD
High Dec 5, 9:12 am
524 JPY 3.37 USD
Low Dec 5, 9:03 am
505 JPY 3.25 USD
Volume
73,800
Trading Value
0.04B JPY 0.25M USD
VWAP
515.93 JPY 3.33 USD
Minimum Trading Value
50,700 JPY 327 USD
Market Cap
0.02T JPY 0.13B USD
Number of Trades
159
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
289
1-Year High Apr 22, 2025
11,342
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 63,900 457,800 7.16
Nov 21, 2025 66,200 460,100 6.95
Nov 14, 2025 72,000 480,800 6.68
Nov 7, 2025 76,600 509,200 6.65
Oct 31, 2025 79,200 530,600 6.70
Company Profile
Japan Tissue Engineering Co., Ltd. is a regenerative medicine venture. The company develops autologous cultured epidermis and cartilage, among other products. It became a subsidiary of Teijin through a tender offer.
Sector
Precision Instruments
Japan Tissue Engineering Co., Ltd. focuses on the development, manufacturing, and sales of regenerative medicine products, as well as contracted regenerative medicine services for development and manufacturing, and research and development support. The company has five products: JACE (autologous cultured epidermis), JACC (autologous cultured cartilage), NEPIC (autologous cultured corneal epithelium), OCULAR (autologous cultured oral mucosal epithelium), and JASMINE (autologous cultured epidermis containing melanocytes). In its contracted regenerative medicine business, the company provides CDMO (Contract Development and Manufacturing Organization) and CRO (Contract Research Organization) services. The research and development support business offers the LabCyte series of human cultured tissues. As new pipelines, the company is working on the development of allogeneic cultured epidermis and CAR-T cell therapies. Japan Tissue Engineering Co., Ltd. is a member of the Teijin Group.